Physician profile
Ethan Craig
NPI 1316239874
$20,735.96
in general payments reported to CMS, 2019-2025
8 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2021: $6,584 · 2022: $8,970 · 2023: $1,696 · 2024: $2,894 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,353 · Food and Beverage: $268 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,353.25 |
| Food and Beverage | $268.49 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16,278.25 | 2021-2024 | Cosentyx |
| Amgen INC. | $2,000.00 | 2022 | |
| Janssen Biotech, INC. | $1,581.43 | 2024 | Tremfya |
| Abbvie INC. | $565.70 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $189.78 | 2022-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Resmed Corp | $16.12 | 2019 | |
| Janssen Scientific Affairs, LLC | $9.69 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Craig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.